Codman & Shurtleff Inc., a Subsidiary of Depuy Synthes Receives FDA Approval for Implantable Device that Treats Spasticity

8/8/2012 8:41:31 AM

Codman & Shurtleff Inc., part of the Depuy Synthes companies, announced Tuesday that it has received a premarket approval from the U.S. Food and Drug Administration to market a neuromodulation product that treats spasticity. The MedStream Programmable Infusion System is an implanted device that can deliver antispasm drug baclofen directly into the spinal canal through a catheter to relieve the symptoms of severe spasticity. Spasticity affects 12 million in the U.S. and is a movement disorder often caused by stroke, cerebral palsy, multiple sclerosis or spinal cord injury.

Read at News Release

Read Article at

Related Companies

News Categories

• News Release

• Food and Drug Administration (FDA)

• Medical Dev. & Diag. - Approvals

• Medical Devices